Mirati Therapeutics (MRTX) Announces FDA Clearance of IND to Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
Tweet Send to a Friend
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that the U.S. Food and Drug Administration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
